New hope for Hard-to-Treat colorectal cancer? drug combo trial launches
NCT ID NCT07644286
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether combining the drug pirfenidone with an immunotherapy (PD-1 inhibitor), and possibly adding focused radiation, can help people with advanced colorectal cancer that hasn't responded to standard treatments. The study will enroll 48 adults aged 18 to 75 with a specific type of colorectal cancer (pMMR/MSS). Researchers will track how long participants live without their cancer growing and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pirfenidone and a PD-1 inhibitor (a type of immunotherapy), with or without focused radiation therapy
What this could lead to
If this works, it could offer a new treatment option for people with advanced colorectal cancer that has stopped responding to standard therapies.
What could go wrong
This is a small, early-phase trial with only 48 participants, so results may not apply to everyone. The combination of drugs and radiation may cause side effects, and there is no guarantee it will shrink tumors or extend life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (CRC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••